Veterinary Medicines

Enteroporc Coli AC (--) - Lyophilisate and suspension for suspension for injection

Authorised
  • Clostridium perfringens, type A, alpha toxoid
  • Clostridium perfringens, type A, beta2 toxoid
  • Clostridium perfringens, type C, beta1 toxoid
  • Escherichia coli, fimbrial adhesin F4ab
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F5
  • Escherichia coli, fimbrial adhesin F6
Download as PDF

Product identification

Medicine name:
Enteroporc Coli AC (--) - Lyophilisate and suspension for suspension for injection
Active substance:
  • Clostridium perfringens, type A, alpha toxoid
  • Clostridium perfringens, type A, beta2 toxoid
  • Clostridium perfringens, type C, beta1 toxoid
  • Escherichia coli, fimbrial adhesin F4ab
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F5
  • Escherichia coli, fimbrial adhesin F6
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Clostridium perfringens, type A, alpha toxoid
    Presentation_strength:≥ 125 rU Reference:Hse Comments:in lyophilisate Index:0
  • Clostridium perfringens, type A, beta2 toxoid
    Presentation_strength:≥ 794 rU Reference:Hse Comments:in lyophilisate Index:1
  • Clostridium perfringens, type C, beta1 toxoid
    Presentation_strength:≥ 3354 rU Reference:Hse Comments:in lyophilisate Index:2
  • Escherichia coli, fimbrial adhesin F4ab
    Presentation_strength:≥ 23 rU Reference:Hse Comments:in suspension Index:3
  • Escherichia coli, fimbrial adhesin F4ac
    Presentation_strength:≥ 19 rU Reference:Hse Comments:in suspension Index:4
  • Escherichia coli, fimbrial adhesin F5
    Presentation_strength:≥ 13 rU Reference:Hse Comments:in suspension Index:5
  • Escherichia coli, fimbrial adhesin F6
    Presentation_strength:≥ 37 rU Reference:Hse Comments:in suspension Index:6
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AB08
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Lyophilisate: vial (glass); suspension: vial (PET), Package_size:Lyophilisate: 1 vial; suspension: 1 vial, Content:Lyophilisate: 10 ml (25 doses); suspension: 50 ml
  • Packaging:Lyophilisate: vial (glass); suspension: vial (glass), Package_size:Lyophilisate: 1 vial; suspension: 1 vial, Content:Lyophilisate: 10 ml (25 doses); suspension: 50 ml
  • Packaging:Lyophilisate: vial (glass); suspension: vial (PET), Package_size:Lyophilisate: 1 vial; suspension: 1 vial, Content:Lyophilisate: 10 ml (10 doses); suspension: 20 ml
  • Packaging:Lyophilisate: vial (glass); suspension: vial (glass), Package_size:Lyophilisate: 1 vial; suspension: 1 vial, Content:Lyophilisate: 10 ml (10 doses); suspension: 20 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • CEVA Santé Animale
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
  • Ceva-Phylaxia Veterinary Biologicals Co. Ltd.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 8/11/2022
Download
Bulgarian (PDF)
Published on: 8/11/2022
Download
Croatian (PDF)
Published on: 8/11/2022
Download
Czech (PDF)
Published on: 8/11/2022
Download
Danish (PDF)
Published on: 8/11/2022
Download
Dutch (PDF)
Published on: 8/11/2022
Download
Estonian (PDF)
Published on: 8/11/2022
Download
Finnish (PDF)
Published on: 8/11/2022
Download
French (PDF)
Published on: 8/11/2022
Download
German (PDF)
Published on: 8/11/2022
Download
Greek (PDF)
Published on: 8/11/2022
Download
Hungarian (PDF)
Published on: 8/11/2022
Download
Icelandic (PDF)
Published on: 8/11/2022
Download
Italian (PDF)
Published on: 8/11/2022
Download
Latvian (PDF)
Published on: 8/11/2022
Download
Lithuanian (PDF)
Published on: 8/11/2022
Download
Maltese (PDF)
Published on: 8/11/2022
Download
Norwegian (PDF)
Published on: 8/11/2022
Download
Polish (PDF)
Published on: 8/11/2022
Download
Portuguese (PDF)
Published on: 8/11/2022
Download
Romanian (PDF)
Published on: 8/11/2022
Download
Slovak (PDF)
Published on: 8/11/2022
Download
Slovenian (PDF)
Published on: 8/11/2022
Download
Spanish (PDF)
Published on: 8/11/2022
Download
Swedish (PDF)
Published on: 8/11/2022
Download

ema-puar-enteroporc-coli-ac-v-5149-par-en.pdf

English (PDF)
Published on: 14/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."